NJ drugmaker faces civil, criminal fines over drug

by Linda A. Johnson

(AP)—A New Jersey-based generic drug maker has agreed to pay $45 million to resolve criminal and civil liability charges for improperly marketing its weight-gain drug to frail seniors.

Officials from Woodcliff Lake-based Par Pharmaceutical Cos. pleaded guilty to a charge of criminal misbranding Tuesday in federal court in Newark.

Par officials admitted they improperly marketed their Megace ES drug for treating anorexia and malnutrition in geriatric patients who did not have AIDS. It's approved for helping .

The company has also agreed to enter into a five-year corporate integrity agreement with and to drop a lawsuit it filed against the U.S. government.

Par agreed in July to be acquired by an affiliate of the private investment firm TPG for $1.84 billion.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

SAP to pay $20M to settle criminal charges

Sep 15, 2011

(AP) -- Business software maker SAP AG on Wednesday said it agreed to pay $20 million to settle criminal charges from the U.S. Department of Justice against a now-defunct subsidiary, TomorrowNow.

Novartis fined $422.5M in marketing, kickback case

Sep 30, 2010

(AP) -- Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, ...

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments